Navigation Links
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
Date:10/29/2012

SAN FRANCISCO, Oct. 29, 2012 /PRNewswire/ -- Principia Biopharma, Inc., a privately-held biopharmaceutical company focused on advancing best-in-class medicines in immunology, autoimmune diseases, and oncology announced that it successfully met its milestone obligations and received its second tranche of funding totaling $12.5 million in July 2012. The investment was led by existing investors New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.  In February 2011, Principia completed a tiered Series A round of financing totaling $36.3 million and received the first tranche of $12 million that same month.  Proceeds from this most recent financing will be used to advance Principia's lead molecule towards the clinic and to develop additional programs enabled by the company's reversible covalent platform.

(Logo: http://photos.prnewswire.com/prnh/20121029/NY01747LOGO)

Martin Babler, CEO of Principia, says, "We are pleased to complete the closing of our second tranche as it provides the necessary funding for Principia to advance our lead compound toward our first clinical trials in 2013. We appreciate the continued support from our current investors as we invest in important treatments for cancer and autoimmune disorders."

EXPANSION OF SENIOR MANAGEMENT TEAM

As part of Principia's growth and its initiatives to bring new medicines to patients, the company has expanded its senior management team with the hiring of Jens Oliver Funk, M.D. as Chief Scientific Officer (C
'/>"/>

SOURCE Principia Biopharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
2. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
3. PDL BioPharma Completes Regular Quarterly Dividend Payment
4. Chester County Biopharmaceutical Firm to Expand, Create 151 New Jobs
5. National Press Club to Host "NEWSMAKER" with PhRMA CEO to Discuss Policy, Budget Threats to Biopharmaceutical Research
6. PDL BioPharma to Present at Upcoming Investor Conferences
7. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
8. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
9. BioWorld Launches Enhanced Biopharma News Site with Data, Analysis
10. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
11. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2, 2014  InfinityQS International, Inc., the global ... announces key client speakers for Infusion Chicago, its ... The event will be held Oct. 9-10, 2014, ... include projects from Coloplast, The Kellogg Company, Biomet, ... King. The two-day event will also include best ...
(Date:10/2/2014)...  AxelaCare Health Solutions, www.axelacare.com , a leading ... it has acquired Advanced Care, a New ... of the transaction were not disclosed. The ... to 18 nationwide and expands AxelaCare,s national home IV ... - New Jersey metro area.  AxelaCare ...
(Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
Breaking Medicine Technology:InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... Health Inc, Morrisville, NC has introduced IronUp, a Liquid ... dietary iron for infants and children who do not ... (Photo: http://photos.prnewswire.com/prnh/20110810/CL49882 ) ... supplement from a bioavailable source of iron that is ...
... 9, 2011 Q2 2011 Highlights (compared to ... 9% to $109.6 million Product revenue rose 17% to $102.6 ... 2% to 37,300 Masimo rainbow revenue rose 26% to $9.1 ... prior period, which included $0.01 in one-time expenses.  Excluding the prior ...
Cached Medicine Technology:YASOO Health Introduces IronUp™ 2Masimo Reports Second Quarter 2011 Financial Results 2Masimo Reports Second Quarter 2011 Financial Results 3Masimo Reports Second Quarter 2011 Financial Results 4Masimo Reports Second Quarter 2011 Financial Results 5Masimo Reports Second Quarter 2011 Financial Results 6Masimo Reports Second Quarter 2011 Financial Results 7Masimo Reports Second Quarter 2011 Financial Results 8
(Date:10/2/2014)... (PRWEB) October 02, 2014 USARAD ... teleradiology and telemedicine solutions provider including its SecondOpinions.com® ... Backhaus have joined its Executive Team as President ... , Brent Backhaus, USARAD’s new President and COO, ... years of progressively responsible experience in commercial-, medical- ...
(Date:10/2/2014)... Social-Engineer, Inc. the leader in security testing and ... a complimentary webinar on Friday, October 31, at 1:00PM ... of the annual Social-Engineer Capture the Flag (SECTF) competition ... explore how to maximize security and employee performance to ... the webinar go to: Free Webinar Registration . ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3
... - Promotes Commercial Products at Major Cardiology Conferences - - ... - Achieves Efficiencies and Conserves Cash by Consolidating R&D ... ... Neovasc Inc. (TSXV: NVC), a,new specialty vascular device company, today reported on ...
... A very difficult-to-treat child leukemia may benefit from the ... launches the cancer but could potentially be reversed ... The study, led by researchers at Children,s Hospital Boston ... in the November 4 issue of Cancer Cell ...
... Rhode Island Hospital researchers have identified genetic proteins, also ... the microscopic level that can signal a precancerous condition ... who are likely to progress to esophageal cancer. This ... journal Clinical Cancer Research . , Barrett,s esophagus ...
... DUBLIN, Calif., Nov 3 SuperGen, Inc. (Nasdaq:,SUPG), ... development,of novel cancer therapies, today announced that James ... scheduled to present at the,Rodman & Renshaw 10th ... the New York Palace Hotel., SuperGen,s presentation ...
... Global Awards Ceremony Featuring Performances by Grammy Award ... Country Music Star Kenny Rogers, OAK BROOK, ... hosted its 24th Annual Awards of Excellence,celebration on ... who have made outstanding contributions to improve the ...
... CONCORD, Mass., Nov. 3 The Melanoma,Foundation of ... to its fall symposium: "Updates in Melanoma Treatment",presented ... Melanoma Program at Dana,Farber Cancer Institute. A portion ... "Immunotherapy: A Panel Presentation," which includes a panel ...
Cached Medicine News:Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 2Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 3Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 4Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 5Health News:Tackling a hard-to-treat childhood cancer by targeting epigenetic changes 2Health News:New research finds markers for esophageal cancer before it develops 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 3
IVUS console...
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
VasoSeal ES is a extravascular arterial sealing. It utilizes a unique temporary arterial locator system which provides an easier and surer method of locating the femoral artery....
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
Medicine Products: